JP2013508344A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013508344A5 JP2013508344A5 JP2012534763A JP2012534763A JP2013508344A5 JP 2013508344 A5 JP2013508344 A5 JP 2013508344A5 JP 2012534763 A JP2012534763 A JP 2012534763A JP 2012534763 A JP2012534763 A JP 2012534763A JP 2013508344 A5 JP2013508344 A5 JP 2013508344A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- metal ion
- salt
- composition according
- active substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 34
- 229910021645 metal ion Inorganic materials 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 16
- 239000013543 active substance Substances 0.000 claims 9
- 238000000034 method Methods 0.000 claims 8
- 239000002245 particle Substances 0.000 claims 8
- 239000000843 powder Substances 0.000 claims 7
- 239000000126 substance Substances 0.000 claims 4
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims 3
- 229960002401 calcium lactate Drugs 0.000 claims 3
- 239000001527 calcium lactate Substances 0.000 claims 3
- 235000011086 calcium lactate Nutrition 0.000 claims 3
- 229920005862 polyol Polymers 0.000 claims 3
- 150000003077 polyols Chemical class 0.000 claims 3
- 230000000975 bioactive effect Effects 0.000 claims 2
- 229920000669 heparin Polymers 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 229940124748 beta 2 agonist Drugs 0.000 claims 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims 1
- 239000001354 calcium citrate Substances 0.000 claims 1
- PWKNEBQRTUXXLT-ZBHRUSISSA-L calcium lactate gluconate Chemical compound [Ca+2].CC(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O PWKNEBQRTUXXLT-ZBHRUSISSA-L 0.000 claims 1
- 229940041131 calcium lactate gluconate Drugs 0.000 claims 1
- HPVJXNNKHRNBOY-UHFFFAOYSA-L calcium;2-hydroxypropanoate;pentahydrate Chemical compound O.O.O.O.O.[Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O HPVJXNNKHRNBOY-UHFFFAOYSA-L 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 150000004683 dihydrates Chemical class 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims 1
- 229960001008 heparin sodium Drugs 0.000 claims 1
- 230000036571 hydration Effects 0.000 claims 1
- 238000006703 hydration reaction Methods 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 239000006104 solid solution Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 229960001967 tacrolimus Drugs 0.000 claims 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229960000257 tiotropium bromide Drugs 0.000 claims 1
- 235000013337 tricalcium citrate Nutrition 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0918450.8A GB0918450D0 (en) | 2009-10-21 | 2009-10-21 | Composition |
| GB0918450.8 | 2009-10-21 | ||
| PCT/GB2010/001955 WO2011048379A2 (en) | 2009-10-21 | 2010-10-21 | Composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013508344A JP2013508344A (ja) | 2013-03-07 |
| JP2013508344A5 true JP2013508344A5 (enExample) | 2013-12-05 |
Family
ID=41426476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012534763A Pending JP2013508344A (ja) | 2009-10-21 | 2010-10-21 | 組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20130004542A1 (enExample) |
| EP (1) | EP2490670B1 (enExample) |
| JP (1) | JP2013508344A (enExample) |
| CN (1) | CN102665684A (enExample) |
| CA (1) | CA2777899C (enExample) |
| GB (1) | GB0918450D0 (enExample) |
| WO (1) | WO2011048379A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9119777B2 (en) | 2008-05-30 | 2015-09-01 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
| PT2410981T (pt) | 2009-03-26 | 2017-05-25 | Pulmatrix Inc | Formulações em pó seco e métodos para tratar doenças pulmonares |
| GB0908129D0 (en) * | 2009-05-12 | 2009-06-24 | Innovata Ltd | Composition |
| AU2011296343B2 (en) | 2010-08-30 | 2015-12-10 | Pulmatrix Operating Company, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
| US20130164338A1 (en) | 2010-08-30 | 2013-06-27 | Pulmatrix, Inc. | Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder |
| PT2621488T (pt) | 2010-09-29 | 2019-02-12 | Pulmatrix Operating Co Inc | Pós secos catiónicos |
| CA3086367A1 (en) | 2010-09-29 | 2012-04-05 | Pulmatrix Operating Company, Inc. | Monovalent metal cation dry powders for inhalation |
| WO2014007773A1 (en) * | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Compositions comprising muscarinic receptor antagonist and sorbitol |
| CN104487075A (zh) | 2012-02-29 | 2015-04-01 | 普马特里克斯公司 | 可吸入干粉剂 |
| US10105316B2 (en) | 2012-07-05 | 2018-10-23 | Arven llac Sanayi Ve Ticaret A.S. | Inhalation compositions comprising muscarinic receptor antagonist |
| WO2014007772A2 (en) | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Inhalation compositions comprising glucose anhydrous |
| WO2014007768A1 (en) * | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dry powder inhaler compositions comprising long acting muscorinic antagonists |
| US20150174064A1 (en) * | 2012-07-05 | 2015-06-25 | Arven IIac Sanayi Ve Ticaret A.S. | Compositions comprising muscarinic receptor antagonist and glucose anhydrous |
| WO2014074797A1 (en) * | 2012-11-09 | 2014-05-15 | Civitas Therapeutics, Inc. | Ultra low density pulmonary powders |
| EA201591218A1 (ru) * | 2012-12-27 | 2015-11-30 | Майкродоуз Терапьютикс, Инк. | Способы и композиции для введения оксибутинина |
| CN104885172B (zh) * | 2012-12-27 | 2019-12-13 | 3M创新有限公司 | 电化学装置及其制造方法 |
| AU2014248455B2 (en) | 2013-04-01 | 2018-12-06 | Pulmatrix Operating Company, Inc. | Tiotropium dry powders |
| JP2015116367A (ja) * | 2013-12-19 | 2015-06-25 | 重人 下山 | 寝具装置、寝具装置制御方法及びプログラム |
| CN103830194A (zh) * | 2014-03-11 | 2014-06-04 | 熊妲妮 | 茚达特罗固体分散体及含有其的药物组合物 |
| CA2965759C (en) | 2014-10-31 | 2023-12-12 | Glaxosmithkline Intellectual Property Development Limited | Powdered polypeptides with decreased disulfide impurities comprising divalent cationic materials |
| WO2017100656A1 (en) * | 2015-12-11 | 2017-06-15 | Otitopic Inc. | Dry powder formulations of aspirin for inhalation |
| JP7334983B2 (ja) * | 2018-01-11 | 2023-08-29 | エンフィスィーマ ソリューションズ ベスローテン フェンノートシャップ | 肺気腫及びその他の形態のｃｏｐｄの治療のための組成物及び方法 |
| GB201817861D0 (en) | 2018-11-01 | 2018-12-19 | Nicoventures Trading Ltd | Gel and crystalline powder |
| AU2022410611A1 (en) * | 2021-12-16 | 2024-07-18 | Alveolus Bio, Inc. | Spray dried inhalable biotherapeutics for the treatment of disease |
| CN115046816B (zh) * | 2022-03-11 | 2025-09-26 | 桂林优利特医疗电子有限公司 | 一种尿液有形成分分析仪用结晶质控物的制备方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8802174D0 (en) * | 1988-02-01 | 1988-03-02 | Quadrant Bioresources Ltd | Method of drying macromolecules |
| WO1990011756A1 (en) | 1989-04-12 | 1990-10-18 | Aberdeen University | Slow release vitreous systems |
| GB9107628D0 (en) | 1991-04-10 | 1991-05-29 | Moonbrook Limited | Preparation of diagnostic agents |
| EP0563455A1 (en) | 1992-03-31 | 1993-10-06 | Purac Biochem B.V. | Particulate solid products containing a lump forming inhibitor |
| ATE222754T1 (de) * | 1992-06-12 | 2002-09-15 | Teijin Ltd | Ultrafeines pulver zur inhalation und dessen herstellung |
| ATE264096T1 (de) | 1994-03-07 | 2004-04-15 | Nektar Therapeutics | Verfahren und mittel zur verabreichung von insulin über die lunge |
| JP3414539B2 (ja) * | 1994-05-11 | 2003-06-09 | 有限会社ドット | 経鼻吸収用組成物 |
| JP3095624B2 (ja) | 1994-07-19 | 2000-10-10 | 株式会社ボッシュオートモーティブシステム | 積層型熱交換器の偏平チューブのろう付け方法 |
| FI970867A7 (fi) | 1994-08-04 | 1997-04-08 | Quadrant Drug Delivery Ltd | Kiinteät, annostelusysteemit hallittua vapautumista varten, joihin sys teemeihin molekyylit on sisällytetty ja menetelmät niiden valmistamise ksi |
| GB9423419D0 (en) | 1994-11-19 | 1995-01-11 | Andaris Ltd | Preparation of hollow microcapsules |
| US6258341B1 (en) * | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
| CZ391297A3 (cs) | 1995-06-07 | 1998-05-13 | Quadrant Holdings Cambridge Limited | Způsob přípravy tenké porovité skelné matrice a prostředek tím získaný |
| US5874064A (en) * | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| GB9621825D0 (en) | 1996-10-19 | 1996-12-11 | Andaris Ltd | Microparticles and their use as therapeutic vehicles |
| WO1999047174A1 (en) | 1998-03-18 | 1999-09-23 | Cambridge Biostability Limited | Amorphous glasses for stabilising sensitive products |
| DK1131059T3 (da) | 1998-11-13 | 2003-06-30 | Jago Res Ag | Tørpulver til inhalation |
| EP1158958B1 (en) | 1999-03-05 | 2007-06-06 | CHIESI FARMACEUTICI S.p.A. | Improved powdery pharmaceutical compositions for inhalation |
| UA75375C2 (en) | 2000-10-12 | 2006-04-17 | Boehringer Ingelheim Pharma | Method for producing powdery preparations for inhaling |
| DE10050995A1 (de) | 2000-10-14 | 2002-04-18 | Boehringer Ingelheim Pharma | Neue Anticholinergika, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE10050994A1 (de) | 2000-10-14 | 2002-04-18 | Boehringer Ingelheim Pharma | Neue als Arneimittel einsetzbare Anticholinergika sowie Verfahren zu deren Herstellung |
| US20020141946A1 (en) * | 2000-12-29 | 2002-10-03 | Advanced Inhalation Research, Inc. | Particles for inhalation having rapid release properties |
| DE10141376A1 (de) | 2001-08-23 | 2003-03-13 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung von Inhalationspulvern |
| DE10141377A1 (de) | 2001-08-23 | 2003-03-13 | Boehringer Ingelheim Pharma | Aufstreuverfahren zur Herstellung von Pulverformulierungen |
| JP2003062074A (ja) * | 2001-08-29 | 2003-03-04 | Tomohiko Hashiba | 吸入装置 |
| DE10203749A1 (de) | 2002-01-31 | 2003-08-14 | Boehringer Ingelheim Pharma | Neue Anticholinergika, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| DE10203741A1 (de) | 2002-01-31 | 2003-08-14 | Boehringer Ingelheim Pharma | Neue Fluorencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| DE10203753A1 (de) | 2002-01-31 | 2003-08-14 | Boehringer Ingelheim Pharma | Neue Xanthencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| EP1480996A1 (en) * | 2002-02-04 | 2004-12-01 | Glaxo Group Limited | Amorphous fluticasone 2-furoate, pharmaceutical compositions thereof and its conversion to the crystalline unsolvated form |
| CA2478327A1 (en) | 2002-03-20 | 2003-10-02 | Advanced Inhalation Research, Inc. | Hgh (human growth hormone) formulations for pulmonary administration |
| AU2003291527A1 (en) | 2002-12-31 | 2004-07-29 | Nektar Therapeutics | Antibody-containing particles and compositions |
| JP2005060330A (ja) * | 2003-08-18 | 2005-03-10 | Tomohiko Hashiba | 球状タンパク質粉体とその製造方法 |
| GB0520794D0 (en) * | 2005-10-12 | 2005-11-23 | Innovata Biomed Ltd | Inhaler |
| PT2410981T (pt) * | 2009-03-26 | 2017-05-25 | Pulmatrix Inc | Formulações em pó seco e métodos para tratar doenças pulmonares |
| US20120083531A1 (en) * | 2009-03-26 | 2012-04-05 | Clarke Robert W | Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining |
-
2009
- 2009-10-21 GB GBGB0918450.8A patent/GB0918450D0/en not_active Ceased
-
2010
- 2010-10-21 JP JP2012534763A patent/JP2013508344A/ja active Pending
- 2010-10-21 CN CN2010800478259A patent/CN102665684A/zh active Pending
- 2010-10-21 WO PCT/GB2010/001955 patent/WO2011048379A2/en not_active Ceased
- 2010-10-21 EP EP10781721.5A patent/EP2490670B1/en not_active Not-in-force
- 2010-10-21 US US13/501,303 patent/US20130004542A1/en not_active Abandoned
- 2010-10-21 CA CA2777899A patent/CA2777899C/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013508344A5 (enExample) | ||
| ES2708218T3 (es) | Método y formulación para inhalación | |
| US20120083531A1 (en) | Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining | |
| JP7048642B2 (ja) | 肺、鼻、舌下および／または咽頭への送達に適した、少なくとも１つの生物活性化合物をロードした多孔質シリカ粒子の製造方法 | |
| JP2013536845A5 (enExample) | ||
| JP7277490B2 (ja) | 肺送達用ラパマイシン粉末 | |
| BR112013029803B1 (pt) | Composições de vancomicina em pó seco | |
| JP7629159B2 (ja) | 吸入用サーファクタント製剤 | |
| JP2003507411A5 (enExample) | ||
| US20250262150A1 (en) | Surfactant Formulations for Inhalation | |
| US20250288516A1 (en) | Surfactant Formulations for Inhalation | |
| WO2002045682A1 (en) | Particulate inhalation carrier | |
| ME02586B (me) | Unapređena suspendovana formulacija beklometazon dipropionata za administraciju putem inhalacije | |
| CA2630772A1 (en) | Respirable powders | |
| JP2025513460A (ja) | 粉末吸入による医薬品の送達 | |
| JP2018524346A (ja) | 肺送達のためのトリプタン粉末 | |
| CN102686232A (zh) | 用于治疗干咳的来自罗望子树种子的多糖聚合物 |